The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Isolda Fernandez
June 25, 2021
During the EHA2021 Virtual Congress, Know AML spoke with Isolda Fernandez, FUNDALEU, Buenos Aires, AR. We asked, Are there any other options to intensive chemotherapy? In this video, Fernandez discusses alternative treatment options to intensive chemotherapy for patients with acute myeloid leukemia. She talks about the advances in this field, the approval of a novel agent targeting genetic mutations, and the combination of venetoclax with azacitidine for older patients who are not fit for intensive chemotherapy.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.